Get notified when TWST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Our Management Will Have Broad Discretion In the Application of the Net Proceeds (new) — Management has wide latitude over the use of proceeds, with no specific allocations disclosed, which limits investor visibility into how the capital will be deployed.
- You Will Experience Immediate Dilution (new) — The offering price is expected to be significantly above net tangible book value per share, resulting in immediate and potentially substantial dilution for new investors.
Twist Bioscience files to raise $250M in common stock offering; terms not yet priced
Filed August 4, 2026 · ~2 min read
Key Changes
-
high
Twist Bioscience is offering $250.0 million of common stock, with a 30-day underwriter option for up to $37.5 million more. This is a primary offering, so proceeds go to the company.
The Offering verify on EDGAR → -
high
The company reported a GAAP net loss of $35.1 million for Q3 FY2026, or $0.56 per diluted share, on revenue of $118.4 million. Adjusted EBITDA was a loss of $11.3 million.
Prospectus Summary verify on EDGAR → -
medium
Net proceeds will fund R&D, manufacturing expansion, product offerings, and general corporate purposes, with broad management discretion. No specific amounts are allocated.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HAIN 10-K) is open in full — no account needed.
Partner
Trade TWST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify